Navigation Links
Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.

AVENTURA, Fla., July 14, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DEGH), the parent company of Fuse Science, Inc. (, announced today that it has entered into a research and development agreement with Platform Delivery Technologies Inc. (PDT Inc.), a California-based pharmaceutical consulting firm. Double Eagle Holdings is the parent company of Fuse Science, Inc., the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

The team at PDT Inc. has been responsible for numerous product formulations currently on the market, including line extensions for Chloraseptic, private label electrolyte replacement formulas for national drugstore chains, Zicam Cold formulas and several prescription pharmaceuticals. The PDT Inc. team has more than 30 pending and issued patents in the pharmaceutical and sports performance industries.

"PDT Inc. has provided exclusive formulations and proprietary branding for many of the world's top pharmaceutical companies. Through this agreement, our ability to bridge into several major product categories is a certainty," said Brian Tuffin, Fuse Science President and Chief Operating Officer. "Our strong working relationship will accelerate our commercialization efforts."

Under the terms of the agreement, PDT Inc. will oversee a team of scientists facilitating the formulation and manufacturing of several Fuse Science products that leverage the Company's industry-leading Fusome Technology. The team's focus will be ongoing product innovation while working to advance Fuse Science's technology, intellectual property and patents. Rob Davidson, the team's managing director, reported today that PDT Inc. has already completed work on three new industry standards and proprietary formulations as Fuse Science prepares to enter the sports nutrition and performance categories. These are:

  • EnerJel – For active muscle fatigue, a real time anti-inflammatory and energy source applied directly to the problem area to help athletes finish the game
  • PowerDrops – Concentrated electrolyte delivery in a single drop before the game for stronger, sustained performance
  • EnergyDrops – An all-natural, faster-acting energy source with longer-lasting results in a single drop

"It is our firm belief that through the Fuse Science formulary technology, we can deliver user benefits faster and more effectively than typical sports drinks, pills and gels that are currently available on the market," added Dr. Edward Maliski, PDT Inc.'s Director of Research and Development.

Fuse Science products will be manufactured in full compliance with current good manufacturing practices (cGMP) set forth by the U.S. Food and Drug Administration, and as the company advances into larger categories, it intends to further maintain strict adherence to all FDA and regulatory compliance standards. In addition, because one of the natural markets for Fuse Science products is in the athletic and fitness space, extreme care has been taken to ensure that all of the company's products are in compliance with the banned substances policies of the world's major sports leagues.

Davidson's PDT Inc. team includes Dr. Maliski and Dr. Eric E. Allen. Dr. Maliski is an accomplished research scientist with 30 years' experience in the development of pharmaceutical and biotechnology products, and whose background includes work for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. A recognized authority in the pharmaceutical industry for his work in drug discovery, Dr. Allen is an inventor on 16 drug-related, issued U.S. patents and brings nearly 25 years of pharmaceutical industry experience, including 10 years at Merck & Co.

"This is another key step in the journey to significant shareholder value," added Tuffin. "We have a tremendous science platform to build on, and this partnership will enhance our efforts. In the coming days and weeks we will begin to announce further strategic partnerships and endorsements from several of America's most notable athletes."

About Double Eagle Holdings

Double Eagle Holdings (OTCQB: DEGH) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Double Eagle Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
7. Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby
8. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
(Date:12/1/2015)... Sverige, December 1, 2015 ... Cancer Study Group (IBCSG, Bern ... ingå i en klinisk studie av palbociclib, ett ... --> Studien, med namn PYTHIA, kommer ... anti-hormonella läkemedel i kombination med palbociclib, som tillhör ...
(Date:11/30/2015)... , Dec. 1, 2015 Researchers have developed ... body part thickness and checks for motion, positioning and ... feasibility study presented today at the annual meeting of ... (RSNA). Steven Don , M.D., associate ... University School of Medicine in St. Louis, ...
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... 2015 , ... PYA’s latest white paper, “ PYA Leadership ... “pain point” for merging or aligning healthcare provider organizations—when mergers and other affiliation ... This quick-read guidance suggests that failing to recognize the power of an effective ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. ... a Modern Man for 2015. , Angeleno Magazine is a division of ... Established in 1994, Modern Luxury includes more than 50 magazine titles across 15 ...
(Date:11/30/2015)... ... 2015 , ... Trevor and Taylor Crabb have unveiled an exciting new ... represent the United States. This hybrid crowdfunding campaign is designed to provide ... in addition to offering corporate sponsors with some great marketing deliverables with the brothers ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... programs of the19th Bi-National Convention of the Federation of Philippine American Chambers of ... in Las Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate ...
Breaking Medicine News(10 mins):